
XY018
CAS No. 1873358-87-2
XY018 ( —— )
产品货号. M33993 CAS No. 1873358-87-2
XY018 是一种有效的 ROR-γ 选择性拮抗剂。XY018 作用于 293T 细胞,抑制 ROR-γ 活性,EC50 为 190 nM。XY018 与 ROR-γ 疏水配体结合域 (LBD) 结合 。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称XY018
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述XY018 是一种有效的 ROR-γ 选择性拮抗剂。XY018 作用于 293T 细胞,抑制 ROR-γ 活性,EC50 为 190 nM。XY018 与 ROR-γ 疏水配体结合域 (LBD) 结合 。
-
产品描述XY018 is a potent ROR-γ-selective antagonist. XY018 inhibits ROR-γ constitutive activity in 293T cells with high potency (EC50, 190 nM). XY018 binds to the ROR-γ hydrophobic ligand binding domain (LBD).
-
体外实验XY018 (0.07-10 μM; 4 days) inhibit CRPC tumors C4-2B cells growth and survival.XY018 inhibits Gal4-RORγ-LBD and Gal4-RORα-LBD with IC50s of 0.19±0.02 and 7.57 μM in 293 T cells, respectively. XY018 shows anti-proliferation effects against the prostate cancer cell lines LNCaP, 22Rv1, C4-2B, DU145, and PC-3 with IC50s of 5.14±0.36, 9.00±0.33, 9.20, 28.43±0.89, and 11.14±1.78 μM, respectively.Cell Viability Assay Cell Line:CRPC tumors C4-2B Concentration:0.07, 0.15, 0.31, 0.62, 1.25, 2.5, 5, and 10 μM Incubation Time:4 days Result:Inhibited growth and survival.
-
体内实验XY018 (5 mg/kg; intraperitoneally i.p.; five times per week for 23 days) inhibit CRPC tumor growth in mice. XY018 (10 mg/kg orally or 2 mg/kg intravenously) exhibits reasonable pharmacokinetics profiles in SD rats.Animal Model:Four-week-old male SCID C.B17 mice (for C4-2B and VCaP) or BALB/c nu/nu athymic mice (for 22Rv1 and PC-3)Dosage:5 mg/kg Administration:Treated intraperitoneally (i.p.); five times per week for 23 daysResult:Tumor growth inhibition.Animal Model:Sprague Dawley rats Dosage:10 mg/kg (po; 1 mg/mL); 2 mg/kg (iv;0.4 mg/mL) (Pharmacokinetic Analysis)Administration:Orally administrated (10 mg/kg) and intravenously administrated (2 mg/kg); single dose Result:High plasma exposure AUC(0–∞) value of 6444 (μg/L·h), half-life (T1/2=7.67±2.36 h) and maximum plasma concentration (Cmax) value of 839 (μg/L) after a 2 mg/kg iv administration.Demonstrated a relatively low oral bioavailability of 19% after an oral administration.
-
同义词——
-
通路Nuclear Receptor/Transcription Factor
-
靶点ROR
-
受体ROR
-
研究领域——
-
适应症——
化学信息
-
CAS Number1873358-87-2
-
分子量516.37
-
分子式C23H15F7N2O4
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO 中的溶解度 : 100 mg/mL (193.66 mM; 超声助溶 )
-
SMILESO=C(CC1=C([N+]([O-])=O)C=CC=C1)NC2=CC=C(C3=CC=C(C(C(F)(F)F)(C(F)(F)F)O)C=C3F)C=C2
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Junjian Wang, et al. ROR-γ Drives Androgen Receptor Expression and Represents a Therapeutic Target in Castration-Resistant Prostate Cancer. Nat Med. 2016 May;22(5):488-96.?
产品手册




关联产品
-
AZD-0284
AZD-0284 是核受体 RORγ 的有效、选择性反向激动剂,可用于治疗斑块型银屑病。
-
Bevurogant
Bevurogant 是 RORγt 受体拮抗剂,可用于治疗慢性炎症性疾病的研究。
-
RORγt inverse agonis...
RORγt 反向激动剂 13 (Compound 3i) 是一种有效的、口服活性的、选择性的 RORγt 反向激动剂 (IC50=63.8 nM),具有改善的化合物样特性。